Increased survival and decreased recurrence in colorectal cancer patients diagnosed in a screening programme

Mengual-Ballester, Mónica; Pellicer-Franco, Enrique; Valero-Navarro, Graciela; Soria-Aledo, Víctor; García-Marín, José Andrés; Aguayo-Albasini, José Luís

doi:10.1016/j.canep.2016.06.003

Cited by 22 publications

(13 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is well-accept that screening programs are able to early detect and decrease mortality from CRC [20], while some will relapse in patients with CRC after underwent potentially curative resection [24–27]. Recurrences are mainly attributed to greater malignancy and poor response to chemotherapy, suggesting that a non-invasive blood based test with high sensitivity and specificity for monitoring the recurrences in patients with CRC will greatly attributed to higher survival.…”

Section: Discussionmentioning

confidence: 99%

Circulating MIC-1/GDF15 is a complementary screening biomarker with CEA and correlates with liver metastasis and poor survival in colorectal cancer

Wang

Yang

Tian³

et al. 2017

Oncotarget

View full text Add to dashboard Cite

Macrophage inhibitory cytokine 1 (MIC-1/GDF15) has been characterized as a candidate biomarker for colorectal cancer (CRC) recently. However, the role of serum MIC-1 in screening patients with early stage CRC and monitoring therapeutic response have not been well-established, particularly in the combination with CEA for the screening and the prejudgment of occurrence with liver metastasis. In this study, we performed a retrospective blinded evaluation of 987 serum samples from 473 individuals with CRC, 25 with adenomatous polyps, and 489 healthy individuals using ELISA or immunoassay. The sensitivity of serum MIC-1 was 43.8% and 38.5% for CRC diagnosis and early diagnosis, respectively, which were independent of and comparatively higher than for CEA (36.6% and 27.3%) at comparable specificity. Serum MIC-1 after surgery were significantly elevated at the time of tumor recurrence, and notable increase were observed in 100% patients with liver metastasis. Besides the TNM classification and differentiation grade, MIC-1 was an independent prognostic factor contributing to overall survival. We conclude that MIC-1 can act as a candidate complementary biomarker for screening early-stage CRC by combination with CEA, and furthermore, for the first time, identify a promising prognostic indicator for monitoring recurrence with liver metastasis, to support strategies towards personalized therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Circulating MIC-1/GDF15 is a complementary screening biomarker with CEA and correlates with liver metastasis and poor survival in colorectal cancer

Wang

Yang

Tian³

et al. 2017

Oncotarget

View full text Add to dashboard Cite

show abstract

“…Considering the association between colon polyps and the incidence of CC, prevention strategies and the effectiveness of health systems, such as detection of precancerous polyps through screening, are recommended in order to prevent this disease [17]. In addition, early detection, finding patients at initial stages of the disease, and early treatment can effectively increase the SR of such patients [18,19].…”

Section: Discussionmentioning

confidence: 99%

Survival rate of colon and rectum cancer in Iran: A systematic review and meta-analysis

Panahi

Hezaveh

et al. 2019

neo

View full text Add to dashboard Cite

Colorectal cancer is one of the deadliest cancers worldwide. Effective screening, surveillance and prevention can decrease its incidence, mortality and burden. This meta-analysis aims to provide a pooled estimation of 5-year survival rate for colorectal cancer based on topography codes and treatment in Iranian population. A systematic search for literature was done in international and national databases up to July 2018. Twenty-seven studies from 4929 articles met the eligible criteria. The overall pooled 5-year survival rates of colorectal cancer, colon, rectal and sigmoid were 56% (95% CI: 49, 63), 53% (95% CI: 41, 65), 52% (95% CI: 41, 62) and 38% (95% CI: 22, 55), respectively. In addition, 5-year survival rate of colorectal cancer after surgery was 64% (95%CI: 50, 78). Subgroup analysis by type of data source showed significantly higher rate of survival in oncology center (29%) than hospital-based (p=0.005). As a conclusion, low survival rate of colorectal cancer in Iran necessitates effective screening and surveillance strategies to find precancerous polyps and detect early-stage cases with lower stage risk of cancer.

show abstract

“…Colonoscopy is the most sensitive and specific test for detecting CRC and its precursors . Detection of CRC, via screening before the patient is symptomatic, is associated with increased survival and decreased recurrence . The Australian National Bowel Cancer Screening Program (NBCSP) was implemented in 2006, and by 2020 faecal occult blood tests (FOBT) will be available biennially to all Australians aged 50‐74 .…”

Section: Introductionmentioning

confidence: 99%

“…2 Detection of CRC, via screening before the patient is symptomatic, is associated with increased survival and decreased recurrence. 3,4 The Australian National Bowel Cancer Screening Program (NBCSP) was implemented in 2006, and by 2020 faecal occult blood tests (FOBT) will be available biennially to all Australians aged 50-74. 1 The current Cancer Council Australia recommendation advises that a +FOBT should be investigated with a diagnostic colonoscopy within 120 days.…”

Section: Introductionmentioning

confidence: 99%

The Direct Access Colonoscopy Clinic: Improving time to colonoscopy for eligible positive faecal occult blood test patients in Broken Hill NSW

Whitelaw

Hammond

Cumming

et al. 2019

Australian J Rural Health

View full text Add to dashboard Cite

Objective This pilot project aimed to assess whether the Direct Access Colonoscopy Clinic is an effective and safe model to reduce the time from a positive faecal occult blood test referral to a gastroenterologist‐performed colonoscopy, and its effect on meeting the 120‐day recommendation. Design Before/after clinical practice and patient file audit. Setting Broken Hill Health Service. Participants De‐identified data from all positive faecal occult blood test colonoscopies performed in the Broken Hill Health Service in October 2016‐January 2017 (Pre‐Direct Access Colonoscopy Clinic) and October 2017‐January 2018 (Post‐Direct Access Colonoscopy Clinic). Main outcome measures Variables included referral date, indication, initial appointment date, colonoscopy date, colonoscopy finding, bowel preparation and adverse events. Colonoscopies indicated by positive faecal occult blood test results were the focus. Results The nurse‐consulted Direct Access Colonoscopy Clinic cohort (n = 22) had a significant 139‐day reduction from positive faecal occult blood test referral to colonoscopy compared to the Pre‐Direct Access Colonoscopy Clinic cohort. All Direct Access Colonoscopy Clinic patients met the new 120‐day recommendation for wait‐time from referral to colonoscopy. Following the introduction of the Direct Access Colonoscopy Clinic, no immediate adverse events were documented for patients using either the conventional or Direct Access Colonoscopy Clinic pathways. Conclusions The Direct Access Colonoscopy Clinic offers a safe and effective intervention that reduces wait‐time to colonoscopy in eligible patients with positive faecal occult blood test within the recommended 120 days. Further research is recommended, but Direct Access Colonoscopy Clinic has the potential to improve timely access to colonoscopy services and outcomes for all positive faecal occult blood test patients.

show abstract

Increased survival and decreased recurrence in colorectal cancer patients diagnosed in a screening programme

Cited by 22 publications

References 24 publications

Circulating MIC-1/GDF15 is a complementary screening biomarker with CEA and correlates with liver metastasis and poor survival in colorectal cancer

Circulating MIC-1/GDF15 is a complementary screening biomarker with CEA and correlates with liver metastasis and poor survival in colorectal cancer

Survival rate of colon and rectum cancer in Iran: A systematic review and meta-analysis

The Direct Access Colonoscopy Clinic: Improving time to colonoscopy for eligible positive faecal occult blood test patients in Broken Hill NSW

Contact Info

Product

Resources

About